PYPD Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (30 May 2024 @ 16:00):

PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs...

Stats
Today's Volume	126.00
Average Volume	2 328.00
Market Cap	7.44M
EPS	$0 ( 2024-05-08 )
Next earnings date	( $0 ) 2024-08-07
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.460
ATR14	$0 (0.00%)

PolyPid Ltd. Correlation

10 Most Positive Correlations
PROC	0.852
AEI	0.837
SCOR	0.824
EKSO	0.806
LBTYK	0.802

10 Most Negative Correlations
HWKN	-0.801

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

PolyPid Ltd. Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-1.82M (0.00 %)
EPS:	$-16.99

FY	2023
Revenue:	$0
Gross Profit:	$-1.82M (0.00 %)
EPS:	$-16.99

FY	2022
Revenue:	$0
Gross Profit:	$-1.72M (0.00 %)
EPS:	$-2.03

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-3.58

Financial Reports:

No articles found.

PolyPid Ltd. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

PolyPid Ltd.

PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.